Novo Holdings REPAIR Impact Fund invests USD12m in Mutabilis and IBT Vaccines
The Novo Holdings REPAIR Impact Fund has made a EUR7 million investment in Mutabilis, a company developing novel antibacterials against Gram-negative infections based near Paris, France.
This investment will allow the company to accelerate its 2G-Dabocins program, a wide spectrum Gram-negative anti-infective agent, which is currently undergoing lead optimisation.
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
 |
BD |
AMR NEWS
Your Biweekly Source for Global AMR Insights!
Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.
Don’t miss out on staying ahead in the global AMR movement—subscribe now!